Osteoarthritis Market Future Growth And Forecast With Significant Players 2019 - 2027
The global osteoarthritis market is
poised to capture a CAGR of approximately 6.8% over the forecast period of
2017-2023, proclaims Market Research Future (MRFR) in a minutely analyzed
research report. The market is growing persistently on account of growing
global geriatric population as it accounts for more disability among the
elderly population than any other disease. Elderly patients have been reported
to experience radiographic osteoarthritis which increases as patients age.
Rising populace of obesity is also considered to be the driving factor in the
growth of the global osteoarthritis market since obesity has also been
identified as a risk factor for osteoarthritis. Obesity reduces the
skeletal-weight-to-body-mass which results in compressive forces to joints.
Although the treatment market for osteoarthritis is not robust, increased
prevalence of the disease has resulted in increased R&D activities which
are expected to bring new treatment options to the market. Moreover, raising
awareness about the disease may induce demand for medications and boost market
growth. Low access to healthcare and the side effects of the treatment
procedures are the most significant hurdles to the growth of the global
osteoarthritis market. Stem cells treatments have been demonstrated as a
possible treatment for osteoarthritis which is expected to provide growth
opportunities to the global osteoarthritis
market.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/1609
Segmentation
The global osteoarthritis market has
been segmented based on type, diagnosis, treatment, and end users. By type, the
osteoarthritis market has been segmented into hip osteoarthritis, wrist
osteoarthritis, spinal osteoarthritis, and others.
By diagnosis, the osteoarthritis market
has been segmented into imaging, joint fluid analysis, and others. The imaging
segment, is sub-segmented into X-rays, magnetic resonance imaging (MRI), and
others.
By treatment, the osteoarthritis has
been segmented into medication, surgery, therapy, and others. The medication
segment has been further segmented into analgesics and non-steroidal
anti-inflammatory drugs, and others. The analgesic sub-segment has been further
segmented into acetaminophen, duloxetine, and others. The non-steroidal
anti-inflammatory drugs sub-segment has been further segmented into aspirin, ibuprofen,
naproxen sodium and naproxen, and others.
By end users, the osteoarthritis
segment has been hospitals & clinics, medical institutes, research
organization, and others.
Regional Analysis
The global osteoarthritis market spans
across the regions of the Americas, Europe, Asia Pacific, and the Middle East
& Africa. The Americas hold the dominant position in the global
osteoarthritis market. A robust healthcare sector, huge osteoarthritis patient
pool, and high healthcare expenditure support the growth of the Americas
market.
Europe has commanded the second
position in the global osteoarthritis market. Availability of funds for
research and development activities coupled with government support, high
healthcare expenditure and growing prevalence of osteoarthritis in the region
propels the growth of the Europe market.
Asia Pacific follows Europe in the
global osteoarthritis market. The presence of a huge patient population, rising
healthcare investments in the developing economies, and the untapped markets of
the region provide a lucrative opportunity for market expansion. Moreover,
favorable government policies aid market growth and will help Asia Pacific to
emerge as the fastest growing market for osteoarthritis.
The Middle East & Africa holds the
least share in the global osteoarthritis market. Poor economic condition and
low penetration of healthcare limit the growth of the market, especially in the
Africa region and the majority of the market share is held by the Middle East
market. The healthcare sector is well-developed in the Gulf countries which
helps the Middle East market progress.
Competitive Landscape
The key players in the global
osteoarthritis market include Regeneron (U.S.), Novartis AG (Europe),
TissueGene Inc. (U.S.), Eli Lilly and Company. (U.S.), Pfizer Inc. (U.S.),
Abbott. (U.S.), Ampio Pharmaceuticals Inc. (U.S.), ABIOGEN PHARMA S.p.A (Europe),
and Merck Sharp & Dohme Corp. (U.S.).
Industry Updates
In August 2018, the FDA launched new
draft guidance for Osteoarthritis Treatments. The new set of rules will guide
drug and medical device manufacturers to develop treatments for
osteoarthritis.
Access Report Details @ https://www.marketresearchfuture.com/reports/osteoarthritis-market-1609
Related
Report: Dysmenorrhea
Treatment Market Research Report- Global Forecast to 2027
Syringe
and Needle Market Research Report - Global Forecast to 2027
Global
Medical Robotics Market Research Report- Forecast To 2027
Global
Neuromodulation Devices Market Research Report- Forecast To 2027
Global
Erythropoietin Drug Market Research Report- Forecast To 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment